The strategic move is seen as a significant step in enhancing Lilly’s capabilities in genetic medicine, adding pressure as broader markets edged lower.Lilly’s $2.4 Billion Orna AcquisitionUnder the terms of the agreement, Lilly will acquire Orna for up to $2.4 billion, which includes an upfront payment and additional payments tied to clinical development milestones.Orna is focused on engineering immune cells in vivo, with its lead program targeting B cell-driven autoimmune diseases through a circular RNA pl ...